Clinical Trial

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.
Protocol Amendment History 3 changes
notable Enrollment increased: 60 -> 200 participants 2026-08-06
minor Trial arms changed: 2 -> 3 2026-08-06
notable Trial sites expanded: 1 -> 12 locations 2026-08-06
Trial Details
NCT Number NCT07137910
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 200 participants
Start Date 2025-09-04
Primary Completion 2026-12-12 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05